S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs) (2014/12/2)|
|Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies (2015/1/9)|
|Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine (2015/1/28)|
|Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera (2015/1/23)|
|Incyte Board Appoints Two New Directors (2015/1/9)|
|Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer (2015/2/26)|
|Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12 (2015/1/27)|
|Incyte to Present at the 33rd Annual J. P. Morgan Healthcare Conference (2014/12/23)|
|Incyte to Present at Upcoming Investor Conferences (2015/2/17)|
|FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera (2014/12/4)|
Click above to view more mutual fund data and stats for incy - Incyte Corp.